Back to top

Ideaya Biosciences initiates monotherapy expansion in IDE892 trial

Ideaya Biosciences (IDYA) announced that initiation of Part 2 monotherapy expansion has been achieved in its Phase 1/2 clinical trial evaluating ID...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

IDEAYA Biosciences, Inc. (IDYA)